EU Approves Incyte’s Minjuvi Combo for Relapsed or Refractory Follicular Lymphoma

Reuters12-18 00:20

EU Approves Incyte’s Minjuvi Combo for Relapsed or Refractory Follicular Lymphoma

Incyte Corporation has announced that the European Commission $(EC)$ has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least one prior systemic therapy. This marks a significant advance as it introduces a chemotherapy-free, CD19- and CD20-dual-targeted immunotherapy option for these patients in Europe. The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use $(CHMP)$ and is based on data from the Phase 3 inMIND trial, which demonstrated a statistically significant improvement in progression-free survival compared to placebo. This is the second EC-approved indication for Minjuvi.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217282673) on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592148999?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 00:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592148999","market":"nz","top_or_hot":-1,"title":"EU Approves Incyte’s Minjuvi Combo for Relapsed or Refractory Follicular Lymphoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      EU Approves Incyte’s Minjuvi Combo for Relapsed or Refractory Follicular Lymphoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation has announced that the European Commission <a href=\"https://laohu8.com/S/EC\">$(EC)$</a> has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least one prior systemic therapy. This marks a significant advance as it introduces a chemotherapy-free, CD19- and CD20-dual-targeted immunotherapy option for these patients in Europe. The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use <a href=\"https://laohu8.com/S/CHMP\">$(CHMP)$</a> and is based on data from the Phase 3 inMIND trial, which demonstrated a statistically significant improvement in progression-free survival compared to placebo. This is the second EC-approved indication for Minjuvi.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217282673) on December 17, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EU Approves Incyte’s Minjuvi Combo for Relapsed or Refractory Follicular Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEU Approves Incyte’s Minjuvi Combo for Relapsed or Refractory Follicular Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 00:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      EU Approves Incyte’s Minjuvi Combo for Relapsed or Refractory Follicular Lymphoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation has announced that the European Commission <a href=\"https://laohu8.com/S/EC\">$(EC)$</a> has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least one prior systemic therapy. This marks a significant advance as it introduces a chemotherapy-free, CD19- and CD20-dual-targeted immunotherapy option for these patients in Europe. The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use <a href=\"https://laohu8.com/S/CHMP\">$(CHMP)$</a> and is based on data from the Phase 3 inMIND trial, which demonstrated a statistically significant improvement in progression-free survival compared to placebo. This is the second EC-approved indication for Minjuvi.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217282673) on December 17, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLbxXF21:1","article_id":"2592148999","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592148999","pubTimestamp":1765988419,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Incyte Corporation has announced that the European Commission  has approved Minjuvi  in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma  after at least one prior systemic therapy. This marks a significant advance as it introduces a chemotherapy-free, CD19- and CD20-dual-targeted immunotherapy option for these patients in Europe. The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use  and is based on data from the Phase 3 inMIND trial, which demonstrated a statistically significant improvement in progression-free survival compared to placebo. This is the second EC-approved indication for Minjuvi.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4532":"文艺复兴科技持仓","INCY":"因塞特医疗","BK4550":"红杉资本持仓","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"欧盟批准Incyte的Minjuvi组合治疗复发或难治性滤泡性淋巴瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"EU Approves Incyte’s Minjuvi Combo for Relapsed or Refractory Follicular Lymphoma\n    \n\n        Incyte Corporation has announced that the European Commission $(EC)$ has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least one prior systemic therapy. This marks a significant advance as it introduces a chemotherapy-free, CD19- and CD20-dual-targeted immunotherapy option for these patients in Europe. The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use $(CHMP)$ and is based on data from the Phase 3 inMIND trial, which demonstrated a statistically significant improvement in progression-free survival compared to placebo. This is the second EC-approved indication for Minjuvi.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217282673) on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592148999","isCrawlerRequest":true}